Pyridine Pyrazine CB2 Receptor Agonists for Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective solutions for conditions such as pain, atherosclerosis, age-related macular degeneration, and ischemia-reperfusion injury, as existing treatments often have limited efficacy and significant side effects, and there is a need for targeted therapies that modulate the Cannabinoid Receptor 2 (CB2) for various inflammatory and fibrotic diseases.
Innovation Solution
Development of novel pyridine and pyrazine derivatives that act as selective agonists or inverse agonists of the CB2 receptor, which have high affinity and selectivity, modulating the receptor's activity to treat a wide range of diseases including pain, inflammation, and fibrosis, by binding specifically to the CB2 receptor with lower activity on the CB1 receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for conditions such as pain, atherosclerosis, and inflammation, then treatment coverage is provided, but efficacy is limited and side effects are significant
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (formula I) that have optimized binding affinity and selectivity parameters for the CB2 receptor. By modifying structural parameters such as the pyridine/pyrazine core, substituent groups (R1-R6), and molecular weight, the invention achieves enhanced therapeutic efficacy while reducing off-target effects and side effects compared to existing therapies.
Solution Approach 2:
The invention applies local quality by designing compounds with specific functional groups positioned at particular locations in the molecule to interact with specific regions of the CB2 receptor. The selective agonist/inverse agonist activity at CB2 versus CB1 receptors is achieved through localized structural features that confer receptor-specific binding, thereby improving efficacy for inflammatory conditions while minimizing central nervous system side effects.
2Adaptability or versatility
If CB1 and CB2 receptor activity is not differentiated, then broad cannabinoid effects are achieved, but central nervous system effects and side effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups positioned at particular locations in the molecule to interact with specific regions of the CB2 receptor. The selective agonist/inverse agonist activity at CB2 versus CB1 receptors is achieved through localized structural features that confer receptor-specific binding, thereby improving efficacy for inflammatory conditions while minimizing central nervous system side effects.
Solution Approach 2:
The invention uses the CB2 receptor as an intermediary target to mediate therapeutic effects for inflammatory and fibrotic conditions without directly activating CB1 receptors. By targeting CB2 selectively, the compounds provide indirect anti-inflammatory and analgesic effects while avoiding the psychoactive and central nervous system side effects associated with CB1 activation.
3Adaptability or versatility
If non-selective cannabinoid receptor modulation is used, then multiple conditions are addressed, but therapeutic precision is reduced
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (formula I) that have optimized binding affinity and selectivity parameters for the CB2 receptor. By modifying structural parameters such as the pyridine/pyrazine core, substituent groups (R1-R6), and molecular weight, the invention achieves enhanced therapeutic efficacy while reducing off-target effects and side effects compared to existing therapies.
Data Source
AI summary
The invention relates to a compound of formula (I)wherein A1, A2, X and R1—R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.